Time-Delayed Anticancer Effect of an Extremely Low Frequency Alternating Magnetic Field and Multimodal Protein–Tannin–Mitoxantrone Carriers with Brillouin Microspectroscopy Visualization In Vitro

Time-Delayed Anticancer Effect of an Extremely Low Frequency Alternating Magnetic Field and Multimodal Protein–Tannin–Mitoxantrone Carriers with Brillouin Microspectroscopy Visualization In Vitro

The effect of an extremely low frequency alternating magnetic field (ELF AMF) at frequencies of 17, 48, and 95 Hz at 100 mT on free and internalized 4T1 breast cancer cell submicron magnetic mineral carriers with an anticancer drug, mitoxantrone, was shown. The alternating magnetic field (100 mT; 17...

Full description

Bibliographic Details
Main Authors:	Anatolii A. Abalymov, Roman A. Anisimov, Polina A. Demina, Veronika A. Kildisheva, Alexandra E. Kalinova, Alexey A. Serdobintsev, Nadezhda G. Novikova, Dmitry B. Petrenko, Alexandr V. Sadovnikov, Denis V. Voronin, Maria V. Lomova
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Biomedicines
Subjects:	magnetic nanoparticles mitoxantrone alternative magnetic field calcium carbonate breast cancer
Online Access:	https://www.mdpi.com/2227-9059/12/2/443

Similar Items

Binding mechanism of anti-cancer chemotherapeutic drug mitoxantrone to DNA characterized by magnetic tweezers
by: Dennis Kreft, et al.
Published: (2018-07-01)

Mitoxantrone in secondarily progressive multiple sclerosis: a series of 18 patients Mitoxantrone na esclerose múltipla secundária progressiva relato de 18 casos
by: María Belén Montú, et al.
Published: (2005-06-01)

Acute myeloid leukaemia induced by mitoxantrone: case report Leucemia mielóide aguda induzida por mitoxantrone: relato de caso
by: Walter Oleschko Arruda, et al.
Published: (2005-06-01)

Mitoxantrone-induced neurotoxicity in CD-1 mice
by: Ana Dias-Carvalho, et al.
Published: (2022-04-01)

Modified Photochemical Properties of Mitoxantrone by Plasmonic Photothermal Response of Hollow Gold Nanoshells
by: Armin Imanparast, et al.
Published: (2019-01-01)

Combined percutaneous ethanol injection and mitoxantrone versus radiofrequency ablation in the treatment of hepatocellular carcinoma
by: Besher Helmy, et al.
Published: (2016-12-01)

Mitoxantrone-Induced Suicidal Erythrocyte Death
by: Markus Arnold, et al.
Published: (2014-11-01)

Mitoxantrone-Surfactant Interactions: A Physicochemical Overview
by: Mirela Enache, et al.
Published: (2016-10-01)

Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Johann de Bono, et al.
Published: (2016-03-01)

Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer
by: Gianpaolo Perletti
Published: (2016-03-01)

The protection of the myocardium by amifostine against mitoxantrone-induced acute cardiotoxicity in rats
by: Vefki Gürhan Kadıköylü, et al.
Published: (2010-06-01)

The protection of the myocardium by amifostine against mitoxantrone-induced acute cardiotoxicity in rats
by: Vefki Gürhan Kadıköylü, et al.
Published: (2010-06-01)

Mitoxantrone Quantification by HPLC-MS/MS in Caco-2 Culture Media
by: Yu. S. Tranova, et al.
Published: (2023-03-01)

Mitoxantrone removal by electrochemical method: A comparison of homogenous and heterogenous catalytic reactions
by: Abbas Jafarizad, et al.
Published: (2017-08-01)

The impact of mitoxantrone on neurological disability in active multiple sclerosis patients
by: Mesaroš Šarlota, et al.
Published: (2004-01-01)

Use of Mitoxantrone in Early Secondary Progressive Multiple Sclerosis: An Observational Study of 48 Patients with Clinical and MRI Outcomes
by: Ahmet Kasım Kılıç, et al.
Published: (2009-06-01)

Evaluation of the PEG Density in the PEGylated Chitosan Nanoparticles as a Drug Carrier for Curcumin and Mitoxantrone
by: Yao Chen, et al.
Published: (2018-07-01)

Fraxetin Interacts Additively with Cisplatin and Mitoxantrone, Antagonistically with Docetaxel in Various Human Melanoma Cell Lines—An Isobolographic Analysis
by: Paula Wróblewska-Łuczka, et al.
Published: (2022-12-01)

Improved anticancer efficiency of Mitoxantrone by Curcumin loaded PLGA nanoparticles targeted with AS1411 aptamer
by: Maryam Hashemi, et al.
Published: (2021-01-01)

Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study
by: Nasim Tabrizi, et al.
Published: (2012-01-01)

Mitoxantrone in the treatment of multiple sclerosis: a single-center experience
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-06-01)

Inflammation as a Possible Trigger for Mitoxantrone-Induced Cardiotoxicity: An In Vivo Study in Adult and Infant Mice
by: Ana Reis-Mendes, et al.
Published: (2021-05-01)

Recrystallization of CaCO3 submicron magnetic particles in biological media
by: Kalinova, Alexandra E., et al.
Published: (2023-12-01)

Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study
by: Rafael Kaliks, et al.
Published: (2010-09-01)

Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study
by: Rafael Kaliks, et al.
Published: (2010-09-01)

Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats
by: Mohamed A. El-Emam, et al.
Published: (2022-03-01)

The Increment of Genoprotective Effect of Melatonin due to “Autooptic” Effect versus the Genotoxicity of Mitoxantrone
by: M Zamani, et al.
Published: (2020-12-01)

Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells
by: Ying Zhang, et al.
Published: (2021-10-01)

Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
by: Harinder Gill, et al.
Published: (2020-05-01)

A Precise Nanostructure of Folate-Overhung Mitoxantrone DNA Tetrahedron for Targeted Capture Leukemia
by: Ying-Zi Bu, et al.
Published: (2020-05-01)

Polymeric mixed micelles loaded mitoxantrone for overcoming multidrug resistance in breast cancer via photodynamic therapy
by: Li ZY, et al.
Published: (2017-09-01)

Degradation of Hybrid Drug Delivery Carriers with a Mineral Core and a Protein–Tannin Shell under Proteolytic Hydrolases
by: Polina A. Demina, et al.
Published: (2022-05-01)

Key Points in Remote-Controlled Drug Delivery: From the Carrier Design to Clinical Trials
by: Denis V. Voronin, et al.
Published: (2021-08-01)

Mitoxantrone-preloaded water-responsive phospholipid-amorphous calcium carbonate hybrid nanoparticles for targeted and effective cancer therapy
by: Wang C, et al.
Published: (2019-02-01)

Co-Encapsulation of Mitoxantrone and β-Elemene in Solid Lipid Nanoparticles to Overcome Multidrug Resistance in Leukemia
by: Kambere Amerigos Daddy J.C., et al.
Published: (2020-02-01)

Vitamin E succinate-conjugated F68 micelles for mitoxantrone delivery in enhancing anticancer activity
by: Liu Y, et al.
Published: (2016-07-01)

Tumor microenvironment-responsive micelles assembled from a prodrug of mitoxantrone and 1-methyl tryptophan for enhanced chemo-immunotherapy
by: Ru Wang, et al.
Published: (2023-12-01)

In vivo evaluation of Sono-chemo therapy via hollow gold nanoshells conjugated to mitoxantrone on breast cancer
by: Vahid Abolzadeh, et al.
Published: (2023-03-01)

Identification of key genes and specific pathways potentially involved in androgen-independent, mitoxantrone-resistant prostate cancer
by: Zhu S, et al.
Published: (2019-01-01)

Pharmacokinetics, distribution and anti-tumor efficacy of liposomal mitoxantrone modified with a luteinizing hormone-releasing hormone receptor-specific peptide
by: Zhang L, et al.
Published: (2018-02-01)